{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Auclair M"],"funding":["ViiV Healthcare"],"pagination":["e0226924"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6977740"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["<h4>Objectives</h4>Aging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity. Protease inhibitors have been associated with cardiometabolic risk, integrase-strand-transfer-inhibitors (INSTI) with weight gain and the CCR5 inhibitor maraviroc with improved vascular function. We have previously reported that the INSTI dolutegravir and maraviroc improved, and ritonavir-boosted atazanavir(atazanavir/r) worsened, inflammation and senescence in human coronary artery endothelial cells (HCAEC)s from adult controls. Here, we analyzed the pathways involved in the drugs' effects on inflammation, senescence and also insulin resistance.<h4>Methods</h4>We ana"],"journal":["PloS one"],"pubmed_title":["HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells."],"pmcid":["PMC6977740"],"funding_grant_id":["research grant paid to Sorbonne University"],"pubmed_authors":["Capeau J","Fellahi S","Guenantin AC","Auclair M","Garcia M"],"additional_accession":[]},"is_claimable":false,"name":"HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.","description":"<h4>Objectives</h4>Aging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity. Protease inhibitors have been associated with cardiometabolic risk, integrase-strand-transfer-inhibitors (INSTI) with weight gain and the CCR5 inhibitor maraviroc with improved vascular function. We have previously reported that the INSTI dolutegravir and maraviroc improved, and ritonavir-boosted atazanavir(atazanavir/r) worsened, inflammation and senescence in human coronary artery endothelial cells (HCAEC)s from adult controls. Here, we analyzed the pathways involved in the drugs' effects on inflammation, senescence and also insulin resistance.<h4>Methods</h4>We ana","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-05-07T01:46:23.567Z","creation":"2020-05-22T09:48:14Z"},"accession":"S-EPMC6977740","cross_references":{"pubmed":["31971958"],"doi":["10.1371/journal.pone.0226924"]}}